Multiplex Platform:
The Multiplex technology opens the door to many applications in human healthcare and creates huge opportunities for innovative findings (e.g. serological signatures). InfYnity Biomarkers has proven the power of this multiparametric technology by identifying an innovative Chagas biomarker to monitor treatment failure/success:
- Zrein M. et al. (2018) A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients. PNTD 12(2): e0006226.
- GranjonE. et al. (2016) Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease. PNTD 10(4): e0004596.
Platform Parameters | Advantages in comparison with ELISA monoplex | ||
96-well microplate format | ![]() |
![]() |
ADVANTAGE 3
Enriching information
|
Scan in one short up to 100 different proteins ( antigens, antibodies,..) in duplicate | ADVANTAGE 4
Outcome significance
|
||
Highly informative profile in single well | ADVANTAGE 5
Sensitive
Multiplex is 8X more sensitive as monoplex ( detection limit at high sample dilution ) |
||
Results can be read either visually or through a reader |
Identification and comparison between different biomarkers | Biomarker Discovery |
Proteins | |
Antibodies | |
Pollutants ( e.g. pesticides) | |
Allergens | |
Immunoprofiling | Vaccination |
Prognosis | |
Patient stratification | |
Drug treatments | |
Fine-tune the composition of antigens mix | Achieve better specificity and sensitivity |
Identify antigen causing a false reactivity | |
Replacing an antigen in the mix |
In Vitro Diagnostic | infectiology |
(Auto-)immunity | |
Allergy | |
Oncology | |
Neurodegenerative Disease | |
Metabolic Disease | |
Cardiovascular Disease | |
Pharmaceutical | Immunotherapy monitoring |
Drug/Vaccine companion | |
Toxicology | |
Stratification | |
Food Industry | Food analysis |
Environment | Toxicology |
- For more information, please contact sales@infynity-biomarkers.com